Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPFZ.L Regulatory News (PFZ)

  • There is currently no data for PFZ

Form 8.3 - Pfizer Inc

20 Nov 2015 15:34

RNS Number : 5084G
Bank of New York Mellon Corp. (The)
20 November 2015
Β 

Ap19

Β 

Β 

FORMΒ 8.3

Β 

IRISHΒ TAKEOVERΒ PANEL

Β 

DISCLOSUREΒ UNDERΒ RULEΒ 8.3Β OFΒ THEΒ IRISHΒ TAKEOVERΒ PANEL ACT,Β 1997,Β TAKEOVERΒ RULES,Β 2013

Β 

DEALINGSΒ BYΒ PERSONSΒ WITHΒ INTERESTSΒ INΒ RELEVANTΒ SECURITIESΒ REPRESENTINGΒ 1%Β ORΒ MORE

Β 

1. KEYΒ INFORMATION

Β 

Name of person dealing (Note 1)

The Bank of New York Mellon Corporation and its subsidiaries, 1.

The Bank of New York Mellon, 2. The Dreyfus Corporation, 3. Mellon Capital Management Corporation, 4. The Boston Company Asset Management LLC, 5. Newton Investment Management Limited, 6. BNY Mellon Capital Markets, LLC, 7. BNY Mellon Service Kapitalanlage-Gesellschaft mbH, 8. The Bank of New York Mellon Trust Company, National Association, 9. BNY Mellon Trust Company (Cayman) Limited, 10. BNY Mellon Trust of Delaware, 11. BNY Mellon, National Association, 12. Lockwood Advisors, Inc., 13. Pershing LLC.

Company dealt in

Pfizer Inc

Class of relevant security to which the dealings being disclosed relate (Note 2)

US$0.05 common stock

Date of dealing

19 November 2015

Β Β 

Β 

2. INTERESTSΒ ANDΒ SHORTΒ POSITIONS

Β 

(a) InterestsΒ andΒ shortΒ positionsΒ (followingΒ dealing)Β inΒ theΒ classΒ ofΒ relevantΒ securityΒ dealtΒ inΒ (NoteΒ 3)

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

99,245,197 1.6078%

7,640 0.00012%

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

8,300 0.0001%

1,700 0.00003%

Total

99,253,497 1.6080%

9,340 0.00015%

Β 

(b) InterestsΒ andΒ shortΒ positionsΒ inΒ relevantΒ securitiesΒ ofΒ theΒ company,Β otherΒ thanΒ theΒ classΒ dealtΒ inΒ (NoteΒ 3)

Class of relevant security:

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

Β 

(2) Derivatives (other than options)

Β 

(3) Options and agreements to purchase/sell

Total

Ap20

Β 

Β 

1. DEALINGSΒ (NoteΒ 4)

Β 

(a) PurchasesΒ andΒ sales

Β 

Β 

Purchase/sale

Β 

Number of relevant securities

Β 

Price per unit (Note 5)

Sale

Sale

Purchase

Purchase

Sale

Transfer Out

Sale

Purchase

Sale

Purchase

Sale

Sale

Β 

147

4

1

309

32

35

14,409

1,234

966

146,523

151,595

6,234

Β 

USD 32.23

USD 32.82

USD 32.29

USD 32.17

USD 32.1625

N/A

USD 32.29

USD 32.14

USD 32.29

USD 32.39

USD 32.36

USD 32.29

Β 

Β 

Β 

(b) DerivativesΒ transactionsΒ (otherΒ thanΒ optionsΒ transactions)

Β 

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(Note 5)

Β 

Β 

(c) OptionsΒ transactionsΒ inΒ respectΒ ofΒ existingΒ relevantΒ securities

Β 

Β 

(i) Writing,Β selling,Β purchasingΒ orΒ varying

Β 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

Call Option

Purchase

200

USD 32

American

15 Jan 2016

USD 1.64

Call Option

Purchase

100

USD 35

American

20 Jan 2017

USD 2.22

Β 

(ii) Exercising

Β 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

Β 

Β 

(d) OtherΒ dealingsΒ (includingΒ transactionsΒ inΒ respectΒ ofΒ newΒ securities)Β (NoteΒ 4)

Β 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

Ap21

Β 

2. OTHERΒ INFORMATION

Β 

Agreements,Β arrangementsΒ orΒ understandingsΒ relatingΒ toΒ optionsΒ orΒ derivatives

Β 

Β 

Β 

Β 

FullΒ detailsΒ ofΒ anyΒ agreement,Β arrangementΒ orΒ understandingΒ betweenΒ theΒ personΒ disclosing andΒ anyΒ otherΒ personΒ relatingΒ toΒ theΒ votingΒ rightsΒ ofΒ anyΒ relevantΒ securitiesΒ underΒ anyΒ option referredΒ toΒ onΒ thisΒ formΒ orΒ relatingΒ toΒ theΒ votingΒ rightsΒ orΒ futureΒ acquisitionΒ orΒ disposalΒ ofΒ anyΒ relevantΒ securitiesΒ toΒ whichΒ anyΒ derivativeΒ referredΒ toΒ onΒ thisΒ formΒ isΒ referenced.Β IfΒ none,Β this shouldΒ beΒ stated.

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

IsΒ aΒ SupplementalΒ FormΒ 8Β attached?Β (NoteΒ 9) Β YES

Β 

Date of disclosure

20 November 2015

Contact name

Ivan Arias

Telephone number

516-338-3370

If a connected EFM, name of offeree/offeror with which connected

If a connected EFM, state nature of connection (Note 10)

Β 

Β 

Β 

Ap23

SUPPLEMENTALΒ FORMΒ 8

Β 

IRISHΒ TAKEOVERΒ PANEL

Β 

DISCLOSUREΒ UNDERΒ RULEΒ 8.1Β ANDΒ RULEΒ 8.3Β OFΒ THEΒ IRISHΒ TAKEOVERΒ PANELΒ ACT,Β 1997,Β TAKEOVERΒ RULES,Β 2013

Β 

DETAILSΒ OFΒ OPENΒ POSITIONS

Β 

(ThisΒ formΒ shouldΒ beΒ attachedΒ toΒ FormΒ 8.1(a)Β &Β (b)(i),Β FormΒ 8.1(b)(ii)Β orΒ FormΒ 8.3,Β asΒ appropriate)

Β 

OPENΒ POSITIONSΒ (NoteΒ 1)

Product name,

Written, or purchased

Β Number of relevant securities to which the option or derivative relates

Exercise price (Note 2)

Type, e.g. American, European etc.

Expiry date

e.g. call option

Call Option

Written

100

USD 28

American

15-Jan-16

Call Option

Purchased

100

USD 31

American

15-Jan-16

Call Option

Purchased

1,700

USD 36

American

15-Jan-16

Call Option

Purchased

1,000

USD 38

American

15-Jan-16

Call Option

Purchased

600

USD 39

American

15-Jan-16

Put Option

Written

100

USD 28

American

15-Jan-16

Call Option

Written

200

USD 32

American

20-Jan-17

Call Option

Written

100

USD 40

American

20-Jan-17

Call Option

Written

1,300

USD 34

American

18-Mar-16

Call Option

Purchased

600

USD 35

American

18-Mar-16

Call Option

Purchased

100

USD 36

American

18-Mar-16

Put Option

Written

200

USD 32

American

20-Nov-15

Call Option

Purchased

3,800

USD 32

American

18-Dec-15

Call Option

Purchased

100

USD 37

American

18-Dec-15

Β 

Notes

1. WhereΒ thereΒ areΒ openΒ optionΒ positionsΒ orΒ openΒ derivativeΒ positionsΒ (exceptΒ forΒ CFDs),Β fullΒ detailsΒ shouldΒ beΒ given.Β FullΒ detailsΒ ofΒ anyΒ existingΒ agreementsΒ toΒ purchaseΒ orΒ toΒ sellΒ must alsoΒ beΒ givenΒ onΒ thisΒ form.

2. ForΒ allΒ pricesΒ andΒ otherΒ monetaryΒ amounts,Β theΒ currencyΒ must beΒ stated.

ForΒ fullΒ detailsΒ ofΒ disclosureΒ requirements,Β seeΒ RuleΒ 8Β ofΒ theΒ Rules.Β IfΒ inΒ doubt,Β consultΒ theΒ Panel.

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
ISEBMBATMBTTBFA
Date   Source Headline
23rd May 201411:55 amRNSForm 8.3 - Pfizer, Inc.
23rd May 201411:53 amRNSForm 8.3 - [Pfizer Inc]
23rd May 201411:46 amRNSForm 8.5 (EPT/RI)-Pfizer Inc.
23rd May 201411:44 amRNSForm 8.3 - Pfizer Inc
23rd May 201411:27 amRNSForm 8.3 - Pfizer Inc
23rd May 201411:08 amRNSForm 8.5 (EPT/RI)
23rd May 201411:07 amRNSForm 8 (DD) - [Pfizer Inc]
23rd May 201411:00 amRNSRule 2.10 Announcement
23rd May 201410:55 amRNSForm 8.5 (EPT/RI) Pfizer Inc
23rd May 201410:53 amRNSForm 8.5 (EPT/RI) Pfizer Inc
23rd May 201410:51 amRNSForm 8.5 (EPT/RI) Pfizer Inc
23rd May 201410:07 amRNSRule 2.10 Announcement
22nd May 20146:05 pmRNSForm 8 (DD) - [Pfizer Inc] - Amendment
22nd May 20143:53 pmRNSForm 8.3 - AstraZeneca PLC
22nd May 20143:48 pmRNSForm 8.3 - Pfizer Inc
22nd May 20143:24 pmBUSForm 8.3 - Pfizer Inc
22nd May 20143:10 pmRNSForm 8.3 - Pfizer Inc
22nd May 20143:09 pmRNSForm 8.3 - [PFIZER INC]
22nd May 20143:02 pmRNSForm 8.3 - [Astrazeneca/Pfizer]
22nd May 20143:01 pmBUSForm 8.3 - Pfizer Inc.
22nd May 20142:59 pmRNSForm 8.3 - Pfizer Inc
22nd May 20142:49 pmRNSForm 8 (DD) - Pfizer Inc.
22nd May 20142:45 pmRNSForm 8 (DD) - Pfizer Inc. - Amendment
22nd May 20142:42 pmBUSForm 8.3 - Pfizer Inc
22nd May 20142:36 pmRNSForm 8.3 - [Pfizer Inc]
22nd May 20142:27 pmRNSForm 8.3 - Pfizer Inc
22nd May 20142:00 pmRNSForm 8.3 - Astrazeneca PLC
22nd May 20142:00 pmBUSForm 8.3 - Pfizer Inc.
22nd May 20141:59 pmRNSForm 8.3 - Pfizer Inc
22nd May 20141:49 pmRNSForm 8.5 (EPT/RI) Replacement Pfizer Inc
22nd May 20141:45 pmRNSForm 8.3 - Pfizer Inc
22nd May 20141:45 pmRNSForm 8.5 (EPT/RI) Replacement Pfizer Inc
22nd May 20141:39 pmRNSForm 8.3 - Pfizer Inc
22nd May 20141:39 pmRNSForm 8.5 (EPT/RI) Replacement Pfizer Inc
22nd May 20141:29 pmRNSForm 8.5 (EPT/RI) Replacement Pfizer Inc
22nd May 20141:25 pmRNSForm 8.5 (EPT/RI) Replacement Astrazeneca Plc
22nd May 20141:23 pmRNSForm 8.3 - AstraZeneca Plc
22nd May 201412:27 pmRNSForm 8.5 (EPT/NON-RI)
22nd May 201412:24 pmRNSForm 8.5 (EPT/RI)
22nd May 201412:00 pmRNSForm 8.5 (EPT/RI)-Pfizer Inc.
22nd May 201411:55 amRNSForm 8.3 - Pfizer Inc
22nd May 201411:52 amRNSForm 8.5 (EPT/NON-RI)
22nd May 201411:52 amRNSForm 8.5 (EPT/RI)
22nd May 201411:30 amRNSForm 8.3 - AstraZeneca Plc
22nd May 201411:14 amRNSForm 8.5 (EPT/RI)
22nd May 201411:13 amRNSForm 8 (DD) - [Pfizer Inc]
22nd May 201411:00 amRNSRule 2.10 Announcement
22nd May 201410:54 amBUSForm 8.3 - Pfizer Inc
22nd May 201410:50 amRNSForm 8.5 (EPT/RI) Pfizer Inc
22nd May 201410:50 amRNSForm 8.5 (EPT/RI) Pfizer Inc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.